See the DrugPatentWatch profile for dextroamphetamine
Generic dextroamphetamine is available, and it is marketed under several brand names.
What are the brand names for dextroamphetamine?
Dextroamphetamine is available under brand names such as Dexedrine, ProCentra, and Zenzedi [1][2]. These medications are prescribed for conditions like Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy [1].
How does generic dextroamphetamine work?
Dextroamphetamine is a central nervous system stimulant that works by increasing the levels of certain neurotransmitters in the brain, primarily dopamine and norepinephrine. This increase helps to improve focus, attention, and impulse control in individuals with ADHD, and promotes wakefulness in those with narcolepsy [1].
What are the risks associated with dextroamphetamine?
Like other stimulant medications, dextroamphetamine carries potential risks. These can include cardiovascular problems such as increased blood pressure and heart rate, psychiatric issues like new or worsening behavioral and thought problems, and a risk of abuse and dependence [1]. It is important for patients to discuss their medical history and any concerns with their healthcare provider before starting this medication.
How does dextroamphetamine compare to other ADHD medications?
Dextroamphetamine is one of several stimulant medications used to treat ADHD. Other common stimulants include methylphenidate (e.g., Ritalin, Concerta) and amphetamine salts (e.g., Adderall). While all these medications work by influencing neurotransmitters, they differ in their chemical composition and how they are processed by the body, which can lead to variations in effectiveness and side effect profiles among individuals [3].
When do patents for dextroamphetamine products expire?
Information on specific patent expirations for dextroamphetamine products can be found on resources like DrugPatentWatch.com [4]. Patent expiration dates are crucial for determining when generic versions of a drug can enter the market, potentially lowering costs for consumers.
Sources:
[1] https://www.webmd.com/drugs/2/drug-7648/dextroamphetamine-oral/details
[2] https://www.drugs.com/drug-master/dextroamphetamine-elixir-5431.html
[3] https://www.additudemag.com/medication-for-adhd-stimulants-vs-nonstimulants/
[4] https://drugpatentwatch.com/